







HHCP-3D Human Hepatocytes Cryopreserved Plateable and for 3D culture Cell Specification – Certificate of Analysis (CoA)	
Lot HH230330	Batch Release: May 27, 2024

Donor data	
Species: Human	Gender: female Age: 70 years
Diagnosis: CCC (Cholangiocellular carcinoma) Medical History: Hypertension Therapy: Hemihepatectomy right	Medication: Arcoxia, Ramidipin, Torem, Pantozol, Spironolacton, Nitrospray, Formoterol, Budenosid Serology: HAV, HBV, HCV, HIV 1/2: negative

Cryopreservation and Thawing	
Cryopreservation: Date: Mar 31, 2023 Amount per vial: 9.97 x 10 ⁶ cells	Thawing: Post-thaw viability: 90.6 % Post-thaw yield per vial: 3.2 x 10 ⁶ cells Recovery: 32 %

2D culture	
Phase contrast on day 1 after thawing (24well plate)	Phase contrast on day 3 after thawing (24well plate)
	

<p>Phase contrast on day 1 after thawing (96well plate)</p>	<p>Phase contrast on day 3 after thawing (96well plate)</p>
	
<p>Recommended seeding density on collagen-coated plates: 24well plate – 400,000 cells/well // 96well plate – 70,000 cells/well. Culture in Human Hepatocyte Maintenance Medium (HHMM).</p>	

<p>3D culture</p>	
<p>Cells seeded in 96well ULA round bottom plates (FaCellitate), 2500 cells/well</p>	
<p>day 10</p>	<p>day 14</p>
 <p>scale bar 100 µm</p>	 <p>scale bar 100 µm</p>

Suspension culture

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5×10^6 cells in 0.5 ml HPM-Cryo):

Time (h)	0	1	2	3	4	5
Viability (%)	90.6	78.7	82.7	77.2	85.3	74.6

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: J. Schuldt

Verified by: K. Damrau